SPR965, a Dual PI3K/mTOR Inhibitor, as a Targeted Therapy in Ovarian Cancer

SPR965 is an inhibitor of PI3K and mTOR C1/C2 and has demonstrated anti-tumorigenic activity in a variety of solid tumors. We sought to determine the effects of SPR965 on cell proliferation and tumor growth in human serous ovarian cancer cell lines and a transgenic mouse model of high grade serous o...

Descripción completa

Detalles Bibliográficos
Autores principales: Tran, Arthur-Quan, Sullivan, Stephanie A., Chan, Leo Li-Ying, Yin, Yajie, Sun, Wenchuan, Fang, Ziwei, Dugar, Sundeep, Zhou, Chunxiao, Bae-Jump, Victoria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7919852/
https://www.ncbi.nlm.nih.gov/pubmed/33659215
http://dx.doi.org/10.3389/fonc.2020.624498

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7919852/
https://www.ncbi.nlm.nih.gov/pubmed/33659215
http://dx.doi.org/10.3389/fonc.2020.624498

Ejemplares similares